Patient characteristics
| . | Values . |
|---|---|
| Sex, male/female, n (%) | 20/7 (74/26) |
| Age at diagnosis, median (range) | 76 (52-90) |
| MDS characteristics | |
| Treatment related, n | 4 |
| WHO classification, n | |
| MDS-SLD | 3 |
| MDS-MLD | 9 |
| CMML-0 | 1 |
| CMML-1 | 1 |
| MDS with isolated del(5q) | 2 |
| MDS-RS-SLD | 3 |
| MDS-RS-MLD | 1 |
| MDS-EB1 | 2 |
| MDS-EB2 | 2 |
| MDS-U | 2 |
| MDS/MPN-U | 1 |
| IPSS cytogenetic risk group, n | |
| Very good | 0 |
| Good | 19 |
| Intermediate | 5 |
| Poor | 1 |
| Very poor | 1 |
| IPSS-R, n | |
| Very low | 5 |
| Low | 15 |
| Intermediate | 3 |
| High | 2 |
| Very high | 1 |
| Cellularity, median % (range) | 60 (20-100) |
| Marrow blasts, median % (range) | 1.8 (0.2-15) |
| Fibrosis, grade 1 or higher | 7 |
| Hemoglobin, g/L, median (range) | 103 (83-138) |
| Absolute neutrophil count ×109, median (range) | 2.7 (0.5-7.8) |
| Platelets ×109/L, median (range) | 161 (13-439) |
| Transfusion dependent Y/N, n | 4/23 |
| MDS treatment, n | |
| ESA | 15 |
| Hypomethylating agents | 3 |
| Lenalidomide | 1 |
| Allogeneic stem cell transplantation | 1 |
| PCD characteristics | |
| MGUS, n | 20 |
| IgG | 12 |
| IgA | 5 |
| FLC | 3 |
| Plasma cells (%), median, range | 3 (0.6-6.6) |
| M-component level at diagnosis, median g/L (range) | 7 (0.5-23) |
| Plasmocytoma, n | 1 |
| Myeloma, n | 6 |
| ISS | |
| Stage I | 0 |
| Stage II | 1 |
| Stage III | 2 |
| Data not available | 1 |
| Smoldering myeloma | 2 |
| IgG | 3 |
| IgA | 2 |
| FLC | 1 |
| Plasma cells %, median (range) | 17 (10.2-39.8) |
| Beta2 microglobulin, median (range) | 3 (1.9-8.25) |
| M-component level at diagnosis, median g/L (range) | 28 (10-87) |
| Myeloma specific therapy, n | |
| Bortezomib | 4 |
| Lenalidomide | 3 |
| Autologous transplantation | 1 |
| . | Values . |
|---|---|
| Sex, male/female, n (%) | 20/7 (74/26) |
| Age at diagnosis, median (range) | 76 (52-90) |
| MDS characteristics | |
| Treatment related, n | 4 |
| WHO classification, n | |
| MDS-SLD | 3 |
| MDS-MLD | 9 |
| CMML-0 | 1 |
| CMML-1 | 1 |
| MDS with isolated del(5q) | 2 |
| MDS-RS-SLD | 3 |
| MDS-RS-MLD | 1 |
| MDS-EB1 | 2 |
| MDS-EB2 | 2 |
| MDS-U | 2 |
| MDS/MPN-U | 1 |
| IPSS cytogenetic risk group, n | |
| Very good | 0 |
| Good | 19 |
| Intermediate | 5 |
| Poor | 1 |
| Very poor | 1 |
| IPSS-R, n | |
| Very low | 5 |
| Low | 15 |
| Intermediate | 3 |
| High | 2 |
| Very high | 1 |
| Cellularity, median % (range) | 60 (20-100) |
| Marrow blasts, median % (range) | 1.8 (0.2-15) |
| Fibrosis, grade 1 or higher | 7 |
| Hemoglobin, g/L, median (range) | 103 (83-138) |
| Absolute neutrophil count ×109, median (range) | 2.7 (0.5-7.8) |
| Platelets ×109/L, median (range) | 161 (13-439) |
| Transfusion dependent Y/N, n | 4/23 |
| MDS treatment, n | |
| ESA | 15 |
| Hypomethylating agents | 3 |
| Lenalidomide | 1 |
| Allogeneic stem cell transplantation | 1 |
| PCD characteristics | |
| MGUS, n | 20 |
| IgG | 12 |
| IgA | 5 |
| FLC | 3 |
| Plasma cells (%), median, range | 3 (0.6-6.6) |
| M-component level at diagnosis, median g/L (range) | 7 (0.5-23) |
| Plasmocytoma, n | 1 |
| Myeloma, n | 6 |
| ISS | |
| Stage I | 0 |
| Stage II | 1 |
| Stage III | 2 |
| Data not available | 1 |
| Smoldering myeloma | 2 |
| IgG | 3 |
| IgA | 2 |
| FLC | 1 |
| Plasma cells %, median (range) | 17 (10.2-39.8) |
| Beta2 microglobulin, median (range) | 3 (1.9-8.25) |
| M-component level at diagnosis, median g/L (range) | 28 (10-87) |
| Myeloma specific therapy, n | |
| Bortezomib | 4 |
| Lenalidomide | 3 |
| Autologous transplantation | 1 |
CMML, chronic myelomonocytic leukemia; EB excess of blasts; ESA, erythropoietin stimulating agent; FLC, free light chain; ISS, International Staging System; MLD, multiple-lineage dysplasia; PCD plasma cell disorder; RS, ring sideroblast, SLD single-lineage dysplasia.